|
Vaccine Detail
Shigella sonnei virG/senA/senB mutant vaccine |
Vaccine Information |
- Vaccine Name: Shigella sonnei virG/senA/senB mutant vaccine
- Target Pathogen: Shigella
- Target Disease: Shigellosis
- Product Name: WRSs2
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Guinea pig
- virG
gene engineering:
- Type: Gene mutation
- Description: This virG/senA/senB mutant is from Shigella sonnei (Barnoy et al., 2010).
- Detailed Gene Information: Click Here.
- senA
gene engineering:
- Type: Gene mutation
- Description: This virG/senA/senB mutant is from Shigella sonnei (Barnoy et al., 2010).
- Detailed Gene Information: Click Here.
- senB
gene engineering:
- Type: Gene mutation
- Description: This virG/senA/senB mutant is from Shigella sonnei (Barnoy et al., 2010).
- Detailed Gene Information: Click Here.
- Immunization Route: Oral immunization
|
Host Response |
Guinea pig Response
- Persistence: A virG, senA, and senB mutant is attenuated in guinea pigs (Barnoy et al., 2010).
- Efficacy: A virG, senA, and senB mutant induces significant protection in guinea pigs from challenge with wild type Shigella sonnei (Barnoy et al., 2010).
- Host IgA response
- Description: Serum GMTs of LPS-specific and Invaplex-specific IgG and IgA were very similar across the three vaccine candidates, indicating that WRSs2 and WRSs3 elicited comparable levels of humoral immune responses in guinea pigs as WRSS1. Antibodies were measured days 0, 7, and 14 after inoculation as well as 2 weeks after challenge. Antibody levels increased greatly between days 0 and 28 (Barnoy et al., 2010).
- Detailed Gene Information: Click Here.
- Host IgG Fc receptor II response
- Description: Serum GMTs of LPS-specific and Invaplex-specific IgG and IgA were very similar across the three vaccine candidates, indicating that WRSs2 and WRSs3 elicited comparable levels of humoral immune responses in guinea pigs as WRSS1. Antibodies were measured days 0, 7, and 14 after inoculation as well as 2 weeks after challenge. Antibody levels increased greatly between days 0 and 28 (Barnoy et al., 2010).
- Detailed Gene Information: Click Here.
|
References |
Barnoy et al., 2010: Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, Venkatesan MM. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine. 2010; 28(6); 1642-1654. [PubMed: 19932216].
|
|